Bristol-Myers Squibb and ZAI Lab enter licensing agreement to develop, manufacture and commercialize brivanib in China

摘要

Bristol-Myers Squibb Company and ZAI Lab Limited (ZAI Lab), a leading innovative biotech company based in China have signed a definitive agreement under which ZAI Lab will acquire exclusive rights in China (including Hong Kong and Macau) to develop, manufacture and commercialize brivanib, an orally available kinase inhibitor in Phase 3 development for oncology indications including hepatocellular carcinoma (HCC).